Abatacept Reduces CD319 + ( SLAMF7 ) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

Study limitation reported by the research below: “Level of evidence assigned as 2 (secondary analysis of an RCT); some may consider this level 3 given the post-hoc, ancillary design.”